Press Releases April 27, 2026 04:10 PM

Arbor Realty Trust Schedules First Quarter 2026 Earnings Conference Call

Arbor Realty Trust Announces Date for Q1 2026 Earnings Release and Conference Call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ABR

Arbor Realty Trust, a NYSE-listed real estate investment trust and lender, will release its first quarter 2026 financial results prior to market open on May 8, 2026, and host a conference call to discuss the results. The company specializes in multifamily and single-family rental loans and manages a large servicing portfolio across various commercial real estate assets.

Arbor Realty Trust Schedules First Quarter 2026 Earnings Conference Call
ABR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Arbor Realty Trust scheduled to report Q1 2026 earnings on May 8, 2026, before market open.
  • Conference call and webcast available for investors to discuss financial results.
  • Company focuses on multifamily and single-family rental real estate lending and servicing, including government-sponsored enterprise products.

UNIONDALE, N.Y., April 27, 2026 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that it is scheduled to release first quarter 2026 financial results before the market opens on Friday, May 8, 2026. The Company will host a conference call to review the results at 10:00 a.m. Eastern Time on May 8, 2026.

A live webcast and replay of the conference call will be available at www.arbor.com in the investor relations section of the Company’s website. Those without web access should access the call telephonically at least ten minutes prior to the conference call. The dial-in numbers are (800) 267-6316 for domestic callers and (203) 518-9783 for international callers. Please use participant passcode ABRQ126 when prompted by the operator.

A telephonic replay of the call will be available until May 15, 2026. The replay dial-in numbers are (800) 938-1603 for domestic callers and (402) 220-1549 for international callers.

About Arbor Realty Trust, Inc.

Arbor Realty Trust, Inc. (NYSE: ABR) is a nationwide real estate investment trust and direct lender, providing loan origination and servicing for multifamily, single-family rental (SFR) portfolios, and other diverse commercial real estate assets. Headquartered in New York, Arbor manages a multibillion-dollar servicing portfolio, specializing in government-sponsored enterprise products. Arbor is a leading Fannie Mae DUS® lender, Freddie Mac Optigo® Seller/Servicer, and an approved FHA Multifamily Accelerated Processing (MAP) lender. Arbor’s product platform also includes bridge, CMBS, mezzanine, and preferred equity loans. Rated by Standard and Poor’s and Fitch Ratings, Arbor is committed to building on its reputation for service, quality, and customized solutions with an unparalleled dedication to providing our clients excellence over the entire life of a loan.

Contact:
Arbor Realty Trust, Inc.
Investor Relations
516-506-4200
[email protected] 


Risks

  • Uncertainties related to the financial performance for Q1 2026 until results are disclosed, which could be affected by real estate market conditions.
  • Potential impact from changes in government-sponsored enterprise policies or mortgage lending regulations affecting Arbor's lending and servicing business.
  • Exposure to the multifamily and single-family rental markets subjects the company to sector-specific economic and market risks, including interest rate fluctuations and housing demand variability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026